MK-1167
Phase 2- Indications
- Alzheimer's disease
Company intelligence / Profile preview
Hyperion Therapeutics, Inc.
Brisbane, California, United Stateshyperioneye.com ↗
- Ownership
- Private
- Employees
- ~100
- Development stage
- Phase 2
01
Overview
Prior to its acquisition by Horizon Pharma in May 2015, Hyperion marketed two FDA-approved therapies—Ravicti and Buphenyl—for urea cycle disorders. Ravicti showed strong sales growth year-over-year. The company also acquired Andromeda Biotech and its late-stage asset DiaPep277 for new-onset type I diabetes, which was in a confirmatory Phase III trial at the time of acquisition[3][6][10].
After the $1.1B acquisition by Horizon Pharma, all programs were integrated into Horizon's portfolio[1][3].
No new independent clinical results have been reported under the Hyperion name since the merger.
Pipeline breadth at time of acquisition included three main programs/products.
- Therapeutic areas
- Metabolic DisordersEndocrinology
- Modalities
- Small molecules (Ravicti, Buphenyl)Peptide immunotherapy (DiaPep277)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Hyperion Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hyperion Therapeutics, Inc..